HOUSTON, May 11, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 270+ patents issued and pending focused on the development ...
On May 16, 2025, FibroBiologics, Inc. (NASDAQ:FBLG) announced a poster presentation at the Society for Investigative Dermatology (SID) Annual Meeting. The poster entitled “Immunomodulatory Potential ...
Please provide your email address to receive an email when new articles are posted on . A master cell bank has been completed for a product that will utilize fibroblasts to treat chronic wounds.
HOUSTON, March 19, 2024 /PRNewswire/ -- FibroBiologics, Inc., (Nasdaq: FBLG) ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending with a focus on the ...
HOUSTON, April 04, 2024 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG), ("FibroBiologics"), a clinical-stage biotechnology company with 150+ patents issued and pending for the development of ...
A new study reviews how cancer-associated fibroblasts (CAFs) influence lymph node metastasis. Researchers identified various CAF subsets that interact with the tumor microenvironment, promoting cancer ...
A small clinical trial led by Dana-Farber Cancer Institute researchers has put a Salk Institute idea to the test in patients: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results